Update: A life of cognitive and physical exercise helps you stay sharp in your 70s and beyond

By SharpBrains | September 25, 2020

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing 13 fas­ci­nat­ing brain research find­ings, use­ful resources–and a brain teas­er to test your atten­tion skills. #1. Good news of the month: Elders today are in sig­nif­i­cant­ly bet­ter shape–physically and cognitively–than three decades ago #2. A dis­tinc­tion WITH a dif­fer­ence: Actu­al, sus­tained practice–not mere knowledge–is need­ed to…

Read More

Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia

By SharpBrains | September 21, 2020

Boehringer Ingel­heim, Click Ther­a­peu­tics ink $500M+ dig­i­tal ther­a­peu­tics devel­op­ment, com­mer­cial­iza­tion deal (Mobi­Health­News): Inter­na­tion­al phar­ma Boehringer Ingel­heim and pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics have inked a $500 mil­lion-plus deal to joint­ly devel­op and com­mer­cial­ize a dig­i­tal treat­ment for patients with schizophrenia.

Read More

The FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia

By SharpBrains | March 30, 2020

Pear gets FDA clear­ance for insom­nia ther­a­peu­tic (Med­C­i­ty News): “Pear Ther­a­peu­tics received mar­ket­ing autho­riza­tion for its third prod­uct — a dig­i­tal ther­a­peu­tic intend­ed to treat chron­ic insom­nia. Called Som­ryst, the app is avail­able by pre­scrip­tion only. It con­sists of a nine-week pro­gram that includes cog­ni­tive behav­ioral ther­a­py and restrict­ing sleep to a lim­it­ed win­dow of time

Read More

Latest brain research, tools and teasers to think outside the mental health status quo box

By SharpBrains | February 26, 2020

__ Time for a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing a range of  research find­ings, resources, brain teasers and rid­dles to help trans­late emerg­ing neu­ro­science into real-world appli­ca­tions and improve our col­lec­tive brain & men­tal health. New think­ing: Neu­ro­science tips about grat­i­tude, aging, pain and the brain: An inter­view with Dr. Daniel Lev­itin What’s normal?…

Read More

Will digital therapeutics complement or replace stimulant medications to address inattention and “silent” cognitive issues?

By SharpBrains | January 29, 2020

___ Akili Inter­ac­tive: Dig­i­tal pedi­atric ADHD ther­a­peu­tic per­forms well with or with­out accom­pa­ny­ing stim­u­lant ther­a­py (Mobi­Health News): “Dig­i­tal ther­a­peu­tic com­pa­ny Akili Inter­ac­tive has announced the first results of an open-label, mul­ti­site pedi­atric ADHD tri­al pro­vid­ing some patients with the company’s video game-like treat­ment along­side a stim­u­lant med­ica­tion. Accord­ing to the com­pa­ny, both those who received…

Read More

Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health

By SharpBrains | January 4, 2018

___ Pear Ther­a­peu­tics rakes in $50M to devel­op addi­tion­al dig­i­tal ther­a­peu­tics (Mobi­Health­News): “Boston- and San Fran­­cis­­co-based Pear Ther­a­peu­tics, mak­er of a pre­scrip­tion dig­i­tal ther­a­peu­tic plat­form, announced today the clo­sure of $50 mil­lion in Series B fund­ing. The round was led by Sin­­ga­­pore-based invest­ment com­pa­ny Temasek, with par­tic­i­pa­tion from return­ing investors 5AM Ven­tures, Arbore­tum Ven­tures, and…

Read More